PD-L1 expression as a predictive biomarker in cancer immunotherapy

Cited by (1,001)

Items 701–800 of 1,001

1. Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy
   Min Zhang, H. J. Yang, Wenjing Hua, Li Zhong, Zenghui Xu, Qijun Qian · 2019 · Frontiers of Medicine
2. Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma
   Dai Ogata, Tetsuya Tsuchida · 2019 · Current Treatment Options in Oncology
3. Circulating biomarkers predictive of tumor response to cancer immunotherapy
   Ernest Y. Lee, Rajan P. Kulkarni · 2019 · Expert Review of Molecular Diagnostics
4. SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients
   Pengju Li, Jeifei Xiao, Bangfen Zhou, Jinhuan Wei, Junhang Luo, Wei Chen · 2020 · Aging
5. Tryptophan 2,3‐dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma
   Makoto Sumitomo, Kiyoshi Takahara, Kenji Zennami, Tomomi Nagakawa, Yasuhiro Maeda, Kazuya Shiogama, Yasuko Yamamoto, Yoshinari Muto, Takuhisa Nukaya, Masashi Takenaka et al. · 2021 · Cancer Science
6. Expression of PD1/PDL1 in gastric cancer at different microsatellite status and its correlation with infiltrating immune cells in the tumor microenvironment
   Yanli Wang, Yuehua Gong, Zhi Lv, Liang Li, Yuan Yuan · 2021 · Journal of Cancer
7. NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images
   Virginia Liberini, Annapaola Mariniello, Luisella Righi, Martina Capozza, Marco Donatello Delcuratolo, Enzo Terreno, Mohsen Farsad, Marco Volante, Silvia Novello, Désirèe Deandreis · 2021 · Cancers
8. DEPTH2: an mRNA-based algorithm to evaluate intratumor heterogeneity without reference to normal controls
   Dandan Song, Xiaosheng Wang · 2022 · Journal of Translational Medicine
9. Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
   Marco Russano, Giulia La Cava, Alessio Cortellini, Fabrizio Citarella, Alessandro Galletti, Giuseppina Rita Di Fazio, Valentina Santo, Leonardo Brunetti, Alessia Vendittelli, Iacopo Fioroni et al. · 2023 · Current Oncology
10. MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes
    Shinsuke Uraki, Hiroyuki Ariyasu, Asako Doi, Ken Takeshima, Shuhei Morita, Hidefumi Inaba, Hiroto Furuta, Noriaki Fukuhara, Naoko Inoshita, Hiroshi Nishioka et al. · 2020 · International Journal of Molecular Sciences
11. PD-L1 expression in small cell lung cancer
    Takefumi Komiya, Rashna Madan · 2015 · European Journal of Cancer
12. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma
    Xiaoling Shang, Jia Li, Hui Wang, Zhenxiang Li, Jiamao Lin, Dawei Chen, Haiyong Wang · 2020 · International Immunopharmacology
13. Predictive value of the prognostic nutritional index in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
    Handai Xia, Wengang Zhang, Qi Zheng, Yuqing Zhang, Xin Ni Mu, Chenxi Wei, Xiuwen Wang, Yanguo Liu · 2023 · Heliyon
14. Nucleo-cytosolic acetyl-CoA drives tumor immune evasion by regulating PD-L1 in melanoma
    Huina Wang, Xiuli Yi, Xiangxu Wang, Yuqi Yang, Hengxiang Zhang, Hao Wang, Jianru Chen, Baolu Zhang, Sen Guo, Lili Wu et al. · 2024 · Cell Reports
15. Exosomal PD-L1 detection in cancer predictive biomarker for response to immune checkpoint blockade therapy
    Tetsuichi Kansha, Shuai Ma, Hao Wang, Xiaotong Yu, Ying Song, Zhengyang Guo, Jiagui Song, Lixiang Xue, Jianling Yang · 2025 · Frontiers in Immunology
16. Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options
    Jessica M. Moskovitz, Jennifer D. Moy, Tanguy Y. Seiwert, Robert Louis Ferris · 2017 · The Oncologist
17. Management of Urothelial Bladder Cancer in Clinical Practice: Real-World Answers to Difficult Questions
    Nataliya Mar, Farshid Dayyani · 2019 · Journal of Oncology Practice
18. Predictive biomarkers of response to immune checkpoint inhibitors in melanoma
    Caroline A. Nebhan, Douglas Buckner Johnson · 2020 · Expert Review of Anticancer Therapy
19. Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review)
    Wenjie You, Bin Shang, Jian Sun, Xueqing Liu, Lili Su, Shujuan Jiang · 2020 · Oncology Reports
20. Meta-Analysis of PD-L1 Expression As a Predictor of Survival After Checkpoint Blockade
    Andrea Arfè, Geoffrey G. Fell, Brian Michael Alexander, Mark Magdi Awad, Scott J. Rodig, Lorenzo Trippa, Jonathan Daniel Schoenfeld · 2020 · JCO Precision Oncology
21. Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
    Mio Ikeda, Yasuhiro Koh, Shunsuke Teraoka, Koichi Sato, Jun Oyanagi, Atsushi Hayata, Nahomi Tokudome, Hiroaki Akamatsu, Yuichi Ozawa, Katsuya Endo et al. · 2021 · Cancers
22. Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients
    Sebastian A. Omenai, Mustapha Ajani, Clement A. Okolo · 2022 · PLoS ONE
23. Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis
    Ádám D. Széles, Tamás Fazekas, Szilárd Váncsa, Melinda Váradi, Petra Terézia Kovács, Ulrich Krafft, Viktor Grünwald, Boris Alexander Hadaschik, Anita Csizmarik, Péter Hegyi et al. · 2022 · Cancer Immunology Immunotherapy
24. Targeting the Tumor Environment in Squamous Cell Carcinoma of the Head and Neck
    Sandra Schmitz, Jean‐Pascal Machiels · 2016 · Current Treatment Options in Oncology
25. Prolonged estrogen deprivation triggers a broad immunosuppressive phenotype in breast cancer cells
    Daniela Hühn, Pablo Martí‐Rodrigo, Silvana Andrea Mouron, Catherine S. Hansel, Kirsten Tschapalda, Bartłomiej Porębski, Maria Häggblad, Louise Lidemalm, Miguel Quintela-Fandiño, Jordi Carreras Puigvert et al. · 2021 · Molecular Oncology
26. Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
    Chao Cheng, Lingdun Zhuge, Xin Xiao, Siyuan Luan, Yong Yuan · 2022 · Frontiers in Oncology
27. RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination
    Yangyang Zhang, Lingxiu Zeng, Meng Wang, Zhenwei Yang, Hailin Zhang, Liping Gao, Ranran Zhang, Jialong Liu, Wenqing Shan, Ying Chang et al. · 2023 · Journal for ImmunoTherapy of Cancer
28. Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches
    Alireza Tojjari, Anwaar Saeed, Arezoo Sadeghipour, Razelle Kurzrock, Ludimila L. Cavalcante · 2023 · Cancers
29. Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses
    Claire Frances Friedman, Beryl L. Manning‐Geist, Qin C Zhou, Tara E. Soumerai, Aliya Holland, Arnaud Da Cruz Paula, Hunter Green, Melih Arda Ozsoy, Alexia E. Iasonos, Travis J. Hollmann et al. · 2024 · Nature Medicine
30. Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the ugly
    Jacob J. Adashek, Jillian Alyse Moran, Dung Thi Le, Razelle Kurzrock · 2025 · Cancer and Metastasis Reviews
31. Role of noninvasive molecular imaging in determining response
    Ariel E. E. Marciscano, Daniel L.J. Thorek · 2018 · Advances in Radiation Oncology
32. Durvalumab in NSCLC: latest evidence and clinical potential
    Nerea Muñoz-Unceta, Isabel Burgueño, Elizabeth Jiménez, Luis G Paz-Ares · 2018 · Therapeutic Advances in Medical Oncology
33. Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer
    Marra Jai Aghajani, Tara Laurine Roberts, Tao Yang, Charles Eugenio McCafferty, Nicole Caixeiro, Paul DeSouza, Navin Niles · 2019 · Endocrine Connections
34. Noninvasive imaging in cancer immunotherapy: The way to precision medicine
    Yang Du, Yafei Qi, Zhengyu Jin, Jie Tian · 2019 · Cancer Letters
35. Salmonella Breaks Tumor Immune Tolerance by Downregulating Tumor Programmed Death-Ligand 1 Expression
    Man‐Chin Chen, Christian Ronquillo Pangilinan, Che‐Hsin Lee · 2019 · Cancers
36. Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy
    Maria V. Deligiorgi, Gerasimos Siasos, Chrysovalantis Vergadis, Dimitrios T. Trafalis · 2020 · International Immunopharmacology
37. Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
    Chester Kao, Eric Powers, Yuan Shan Wu, Michael Datto, Michelle F. Green, John H. Strickler, Neal Ready, Tian Zhang, Jeffrey Melson Clarke · 2021 · Clinical Lung Cancer
38. Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity
    Shunichi Taki, Kohei Matsuoka, Yuko Nishinaga, Kazuomi Takahashi, Hirotoshi Yasui, Chiaki Koike, Misae Shimizu, Mitsuo Sato, Kazuhide Sato · 2021 · Journal for ImmunoTherapy of Cancer
39. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer
    Yongdong Guo, Ronglin Wang, Junqiang Li, Yang Song, Jie Min, Ting Zhao, Lei Hua, Jingjie Shi, Chao Zhang, Peixiang Ma et al. · 2021 · Frontiers in Immunology
40. Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade
    Alecsandra Gorzo, Diana Galoș, Simona Ruxandra Volovăț, Cristian Virgil Lungulescu, Claudia Cristina Burz, Daniel Genel Sur · 2022 · Life
41. PD-L1-Targeted Radionuclide Therapy Combined with αPD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect
    Xuejun Wen, Xueyuan Zeng, Xingxing Cheng, Xinying Zeng, Jia Liu, Yiren Zhang, Yesen Li, Haojun Chen, Jinxiong Huang, Zhide Guo et al. · 2022 · Molecular Pharmaceutics
42. Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma
    Jiaqi Chen, Ding Zhang, Ying Yuan · 2022 · Clinical and Experimental Medicine
43. Upgrading Treatment and Molecular Diagnosis in Endometrial Cancer—Driving New Tools for Endometrial Preservation?
    Miriam Dellino, Marco Cerbone, Antonio Simone Laganà, Amerigo Vitagliano, Antonella Vimercati, Marco Marinaccio, Giorgio Maria Baldini, Antonio Malvası, Ettore Cicinelli, Gianluca Raffaello Damiani et al. · 2023 · International Journal of Molecular Sciences
44. Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods
    Francesca Maria Porta, Elham Sajjadi, Konstantinos Venetis, Chiara Frascarelli, Giulia Cursano, Elena Guerini‐Rocco, Nicola Fusco, Mariia D. Ivanova · 2023 · Journal of Personalized Medicine
45. Advances and challenges in immunotherapy of small cell lung cancer
    Hanfei Guo, Lingyu Li, Jiuwei Cui · 2020 · Chinese Journal of Cancer Research
46. Cancer Precision Medicine: Why More Is More and DNA Is Not Enough
    Moritz Schütte, Lesley Ann Ogilvie, Damian Tobias Rieke, Bodo M. H. Lange, Marie‐Laure Yaspo, Hans Rudolf Lehrach · 2017 · Public Health Genomics
47. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma
    Fangshi Xu, Yibing Guan, Yubo Ma, Xue Li, Peng Zhang, Xiaojie Yang, Tie Chong · 2021 · Aging
48. ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma
    Aditi Mulgaonkar, Roy M. Elias, Layton Woolford, Bing Guan, Kien Nham, Payal Kapur, Alana L. Christie, Vanina Toffessi Tcheuyap, Nirmish Singla, Isaac Alex Bowman et al. · 2022 · Clinical Cancer Research
49. Role of Genomic Instability in Immunotherapy with Checkpoint Inhibitors.
    George Yaghmour, Manjari K Pandey, Catherine Gorman Ireland, Kruti Patel, Sara E. Nunnery, Daniel Powell, Scott L. Baum, Eric Wiedower, Lee Steven Schwartzberg, Michael Gary Martin · 2016 · PubMed
50. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression
    Hayriye Tatlı Doğan, Merve Meryem Kıran, Burak Bi̇lgi̇n, Aydan Kılıçarslan, Mehmet Alı Nahıt Şendur, Bülent Yalçın, A. Ardıçoğlu, Ali Fuat Atmaca, Berrak Gümüşkaya · 2018 · Diagnostic Pathology
51. The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer
    Caroline Stewart Jansen, Nataliya Prokhnevska, Haydn Thomas Kissick · 2018 · Urologic Oncology Seminars and Original Investigations
52. Immunological classification of gliomas based on immunogenomic profiling
    Qiushi Feng, Lin Li, Mengyuan Li, Xiaosheng Wang · 2020 · Journal of Neuroinflammation
53. TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer
    Teng Li, Han Wang, Jiachen Xu, Chengcheng Li, Yudong Zhang, Guoqiang Wang, Yutao Liu, Shangli Cai, Wenfeng Fang, Junling Li et al. · 2021 · Therapeutic Advances in Medical Oncology
54. Accounting for B-cell Behavior and Sampling Bias Predicts Anti–PD-L1 Response in Bladder Cancer
    Ilya A. Dyugay, Daniil K. Lukyanov, Maria A. Turchaninova, Ekaterina O. Serebrovskaya, Ekaterina A. Bryushkova, Andrew R. Zaretsky, Oybek Khalmurzaev, Vsevolod B. Matveev, Mikhail Shugay, Pavel V. Shelyakin et al. · 2022 · Cancer Immunology Research
55. Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?
    Camilo Jiménez, Gustavo Armaiz-Peña, Patricia L. M. Dahia, Yang Lü, Rodrigo Almeida Toledo, Jeena Mary Varghese, Mouhammed Amir Habra · 2022 · Cancers
56. Tissue-resident memory T cells in the kidney
    Nariaki Asada, Pauline Ginsberg, Nicola Gagliani, Hans‐Willi Mittrücker, Ulf Panzer · 2022 · Seminars in Immunopathology
57. Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors
    Yingming Zhu, Fen qin Zhao, Zhenxiang Li, Jinming Yu · 2018 · Cancer Management and Research
58. Current status of prognostic factors in patients with metastatic renal cell carcinoma
    Jun Teishima, Shogo Inoue, Tetsutaro Hayashi, Akio Matsubara · 2019 · International Journal of Urology
59. Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery: A Review of Applicability across Multiple Solid Tumors
    Stefano Giuliani, Irene Paraboschi, Angus McNair, Myles J. F. Smith, Kenneth Samora Rankin, Daniel S. Elson, Vinidh Paleri, Daniel Richard Leff, Graeme J. Stasiuk, John Anderson · 2024 · Cancers
60. Systemic immune-inflammation index as a predictor of survival in non-small cell lung cancer patients undergoing immune checkpoint inhibition: A systematic review and meta-analysis
    Ye Zhang, Yeye Chen, Chao Guo, Shanqing Li, Cheng Huang · 2025 · Critical Reviews in Oncology/Hematology
61. Targeting PD-L1 Protein: Translation, Modification and Transport
    Ran Wei, Libin Guo, Qingshui Wang, Jin Miao, Hang Fai Kwok, Yao Lin · 2018 · Current Protein and Peptide Science
62. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‐L1 expression in cancer patients
    Mina Nikanjam, David Arguello, Zoran Gatalica, Jeffrey J. Swensen, Donald A. Barkauskas, Razelle Kurzrock · 2019 · International Journal of Cancer
63. Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients
    Xiaofeng Liu, Chunguang Shan, Yingluan Song, Juan Du · 2019 · Frontiers in Oncology
64. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung.
    Yoichi Ohtaki, Kyoichi Kaira, Jun Atsumi, Toshiteru Nagashima, Osamu Kawashima, Takashi Ibe, Mitsuhiro Kamiyoshihara, Ryoichi Onozato, Atsushi Fujita, Tomohiro Yazawa et al. · 2018 · Europe PMC (PubMed Central)
65. Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma
    Hsin‐Yu Kuo, Nai‐Jung Chiang, Chiao‐Hsiung Chuang, Chiung‐Yu Chen, I‐Chin Wu, Ting‐Tsung Chang, Hong‐Ming Tsai, Yih‐Jyh Lin · 2020 · Oncology Research and Treatment
66. Atezolizumab in the treatment of metastatic triple-negative breast cancer
    José Manuel Pérez-García, Jesús Soberino, Fabricio Racca, María Gión, Agostina Stradella, Javier Cortés · 2020 · Expert Opinion on Biological Therapy
67. Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS
    Antonio Ward, Adam B. Keeton, Xi Chen, Tyler Ernest Mattox, Alexander B. Coley, Yulia Y. Maxuitenko, Donald J. Buchsbaum, Troy D. Randall, Gang Zhou, Gary Anthony Piazza · 2020 · MedComm
68. From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy
    Andrea Sesma, Julián Pardo, Mara Cruellas, Eva M. Gálvez, Marta Gascón Ruiz, Dolores Isla, Luis Martínez‐Lostao, Maitane Ocáriz, José Ramón Paño, Elisa Quílez et al. · 2020 · Cancers
69. Prognostic Impact of Memory CD8(+) T Cells on Immunotherapy in Human Cancers: A Systematic Review and Meta-Analysis
    Yao Jin, Aili Tan, Jia Feng, Zexi Xu, Pei‐Wei Wang, Peng Ruan, Ruijun Luo, Yiming Weng, Min Peng · 2021 · Frontiers in Oncology
70. Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma
    Rong Tang, Xiaomeng Liu, Wei Wang, Jie Hua, Jin Xu, Chen Liang, Qingcai Meng, Jiang Liu, Bo Zhang, Xianjun Yu et al. · 2021 · Cancer Cell International
71. Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy
    Mioko Matsuo, Ryuji Yasumatsu, Muneyuki Masuda, Satoshi Toh, Takahiro Wakasaki, Kazuki Hashimoto, Rina Jiromaru, Tomomi Manako, Takashi Nakagawa · 2022 · In Vivo
72. Automating Access to Real-World Evidence
    Marie-Pier Gauthier, Jennifer H. Law, Lisa W. Le, Janice J.N. Li, Sajda Zahir, Sharon Nirmalakumar, Mike Sung, Christopher Pettengell, Steven Aviv, Ryan Chu et al. · 2022 · JTO Clinical and Research Reports
73. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer
    Taihang Shao, Mingye Zhao, Leyi Liang, Wenxi Tang · 2022 · Frontiers in Immunology
74. Machine Learning Quantified Tumor-Stroma Ratio Is an Independent Prognosticator in Muscle-Invasive Bladder Cancer
    Qingyuan Zheng, Zhengyu Jiang, Xinmiao Ni, Yang Song, Panpan Jiao, Jiejun Wu, Lin Xiong, Jingping Yuan, Jingsong Wang, Jun Jian et al. · 2023 · International Journal of Molecular Sciences
75. rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
    Giovanna Polcaro, Luigi Liguori, Valentina Manzo, Annalisa Chianese, Giuliana Donadio, Alessandro Caputo, Giosuè Scognamiglio, Federica Dell’Annunziata, Maddalena Langella, Graziamaria Corbi et al. · 2024 · Molecular Cancer
76. Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms
    Gaurav Goyal, Denise Lau, Alison M. Nagle, Robert Vassallo, Karen L. Rech, Jay Hoon Ryu, Caroline Jane Davidge-Pitts, William Oliver Tobin, Matthew J. Koster, N. Nora Bennani et al. · 2019 · Blood
77. DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors
    Jin‐Sung Chung, Vijay Ramani, Masato Kobayashi, Farjana Jahan Fattah, Vinita Popat, Song Zhang, Ponciano D. Cruz, David E. Gerber, Kiyoshi Ariizumi · 2019 · Clinical Cancer Research
78. Identification of immune-associated lncRNAs as a prognostic marker for lung adenocarcinoma
    Chunming He, Hang Yin, Jiajie Zheng, Jian Tang, Yujie Fu, Xiaojing Zhao · 2021 · Translational Cancer Research
79. Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours
    Naoya Maekawa, Satoru Konnai, Kenji Hosoya, Sangho Kim, Ryohei Kinoshita, Tatsuya Deguchi, Ryo Owaki, Yurika Tachibana, Madoka Yokokawa, Hiroto Takeuchi et al. · 2023 · PLoS ONE
80. High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome
    Nithya Krishnamurthy, Daisuke Nishizaki, Scott Michael Lippman, Hirotaka Miyashita, Mary Nesline, Sarabjot Pabla, Jeffrey M. Conroy, Paul DePietro, Shumei Kato, Razelle Kurzrock · 2024 · Therapeutic Advances in Medical Oncology
81. Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC
    Jinsheng Liu, Yuxiang Cai, Yong-Ze He, Jian Xu, Su-Fang Tian, Zhiqiang Li · 2024 · BMC Cancer
82. Immune Biomarkers for Checkpoint Blockade in Solid Tumors: Transitioning from Tissue to Peripheral Blood Monitoring and Future Integrated Strategies
    Ioannis Panagiotis Trontzas, Konstantinos Nikolaos Syrigos · 2025 · Cancers
83. PD-1, PD-L1 and CTLA-4 in pregnancy-related – and in early-onset breast cancer: A comparative study
    Balázs Ács, Lilla Madaras, Anna‐Mária Tõkés, Kristóf Attila Kovács, Erzsébet Kovács, Magdolna Ozsvári-Vidákovich, Ádám Karászi, Ede Birtalan, Magdolna Dank, Attila Marcell Szász et al. · 2017 · The Breast
84. Increased tumor vascularization is associated with the amount of immune competent PD‑1 positive cells in testicular germ cell tumors
    Jennewein, Lukas, Bartsch, Georg, Gust, Kilian, Kvasnicka, Hans‑Michael, Haferkamp, Axel, Blaheta, Roman, Mittelbronn, Michel, Harter, Patrick, Mani, Jens · 2018 · Oncology Letters
85. Oncolytic Viruses for Multiple Myeloma Therapy
    Christine M. Calton, Kevin R. Kelly, Faiz Anwer, Jennifer S. Carew, Steffan T. Nawrocki · 2018 · Cancers
86. Identification of integrin drug targets for 17 solid tumor types
    Adith S. Arun, Clifford G. Tepper, Kit S. Lam · 2018 · Oncotarget
87. Detection and Characterization of Circulating Tumor Cells in Patients with Merkel Cell Carcinoma
    Sabine Riethdorf, Lina Hildebrandt, Lucie Heinzerling, Ellen Heitzer, Nicole Fischer, Sonja Bergmann, Oliver Mauermann, Julie Waldispuehl‐Geigl, Cornelia Coith, Gerhard Schön et al. · 2019 · Clinical Chemistry
88. Combinational phototherapy and hypoxia-activated chemotherapy favoring antitumor immune responses
    Beibei Ma, Jie Sheng, Ping Wang, 鐘偉 江, Entomack Borrathybay · 2019 · International Journal of Nanomedicine
89. Identification of an Immune-Related Gene Signature to Improve Prognosis Prediction in Colorectal Cancer Patients
    Siqi Dai, Shuang Xu, Ye Yao, Kefeng Ding · 2020 · Frontiers in Genetics
90. Tumor-Derived Extracellular Vesicles and the Immune System—Lessons From Immune-Competent Mouse-Tumor Models
    Marvin Droste, Basant Kumar Thakur, Brian P. Eliceiri · 2020 · Frontiers in Immunology
91. Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa
    Ingrid J.G. Burvenich, Yit Wooi Goh, Nancy Yanan Guo, Hui Kong Gan, Angela Rigopoulos, Diana Cao, Zhanqi Liu, Uwe Ackermann, Christian Werner Wichmann, Alexander Franklin McDonald et al. · 2021 · European Journal of Nuclear Medicine and Molecular Imaging
92. Comprehensive analyses of PBRM1 in multiple cancer types and its association with clinical response to immunotherapy and immune infiltrates
    Qiuan Yang, Rong Shen, Hanlin Xu, Xiaoliang Shi, Lili Xu, Lin Zhang, Xinglong Fan, Xiangfeng Jin · 2021 · Annals of Translational Medicine
93. CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies
    Jennifer Sun, Yixuan Chen, Berit Lubben, Ola Adebayo, Barbara Muz, Abdel Kareem Azab · 2021 · Leukemia Research Reports
94. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival
    Davide Ciardiello, Vincenzo Famiglietti, Stefania Napolitano, Lucia Esposito, Filippo Pietrantonio, Antonio Avallone, Evaristo Maiello, Chiara Cremolini, Teresa Troiani, Erika Martinelli et al. · 2022 · Clinical Colorectal Cancer
95. An electrochemical biosensor for the assessment of tumor immunotherapy based on the detection of immune checkpoint protein programmed death ligand-1
    Xin Du, Yuyang Li, Zhenguo Zhang, Congcong Zhang, Jinchun Hu, Xiuxiu Wang, Renshuai Zhang, Jilong Yang, Lei Zhou, Hongyan Zhang et al. · 2022 · Biosensors and Bioelectronics
96. Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
    Joanne Barnes Weidhaas, Nicholas De Marco, Aaron W Scheffler, Anusha K. Kalbasi, Kirk Wilenius, Emily Rietdorf, Jaya Mini Gill, Mara Heilig, Caroline Desler, Robert Chin et al. · 2022 · Journal for ImmunoTherapy of Cancer
97. Immune biomarkers in the spectrum of childhood noncommunicable diseases
    Chrysanthi L. Skevaki, Jolice van den Berg, Nicholas Jones, Johan Garssen, Peter Vuillermin, Michael Eliad Levin, ALAN L. LANDAY, Harald E. Renz, Philip C. Calder, Catherine A. Thornton · 2016 · Journal of Allergy and Clinical Immunology
98. Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit
    Shumei Kato, Vivek Subbiah, Razelle Kurzrock · 2017 · Journal of the National Comprehensive Cancer Network
99. Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescencein situhybridization (FISH) to select the optimal patients for matched therapy?
    Young Kwang Chae, Ayush Arya, Lauren S. Chiec, Hiral Anil Shah, Ari Joseph Rosenberg, Sandip Pravin Patel, Kirtee Raparia, Jaehyuk Choi, Derek Alan Wainwright, Victoria Meucci Villaflor et al. · 2017 · Oncotarget
100. Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma
     Richard Calvin Turkington, Laura A. Knight, Jaine K. Blayney, Maria Secrier, Rosalie V. Douglas, Eileen E. Parkes, Eilis K Sutton, Leanne S. Stevenson, Damian T McManus, Sophia R. Halliday et al. · 2019 · Gut